Tobin Marcus, Wolfe Research policy and politics head, joins CNBC's 'Squawk Box' to discuss what Trump's pick for HHS ...

Wolfe Research has upgraded Warner Bros. Discovery ( WBD, Financials) to "peer perform" from "underperform," citing a ...

Fintel reports that on November 15, 2024, Wolfe Research initiated coverage of Eli Lilly and (NYSE:LLY) with a Outperform ...

Wolfe Research initiated coverage of Veracyte (VCYT) with an Outperform rating and $50 price target Published first on TheFly – the ...

Wolfe Research initiated coverage of Regeneron (REGN) with an Outperform rating and $1,150 price target Eylea patent litigation concerns had ...

Investors often prefer to invest in shares held by company insiders, as management is typically more aligned with the company’s success and shareholder interests. Currently, insiders own just 0.09% of ...

Wolfe Research upgrades Warner Bros. Discovery to peer perform, citing potential for stable EBITDA and debt reduction through ...

Wolfe Research has recently raised Warner Bros Discovery Inc (WBD) stock to Peer Perform rating, as announced on November 11, 2024, according to Finviz. Earlier, on August 13, 2024, Bernstein had ...

Investing.com - Wolfe Research has upgraded shares of Warner Bros. Discovery (NASDAQ: NASDAQ: WBD) to Peer Perform from ...

Argenx (NASDAQ:ARGX) shares trended higher on Tuesday after Wolfe Research upgraded the Dutch biotech to Outperform from Peer Perform, citing higher confidence in the company's dominance in the ...

Fintel reports that on November 12, 2024, Wolfe Research downgraded their outlook for Alnylam Pharmaceuticals (LSE:0HD2) from Peer Perform to Underperform. There are 1,155 funds or institutions ...